US20220002276A1 - Pyridin-sulfonamide compounds for the treatment of conditions related to interleukin 1 beta - Google Patents
Pyridin-sulfonamide compounds for the treatment of conditions related to interleukin 1 beta Download PDFInfo
- Publication number
- US20220002276A1 US20220002276A1 US17/293,877 US201917293877A US2022002276A1 US 20220002276 A1 US20220002276 A1 US 20220002276A1 US 201917293877 A US201917293877 A US 201917293877A US 2022002276 A1 US2022002276 A1 US 2022002276A1
- Authority
- US
- United States
- Prior art keywords
- halo
- substituted
- alkyl
- alkynyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DWJMBQYORXLGAE-UHFFFAOYSA-N pyridine-2-sulfonamide Chemical class NS(=O)(=O)C1=CC=CC=N1 DWJMBQYORXLGAE-UHFFFAOYSA-N 0.000 title abstract description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 title description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 title description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 113
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 44
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims abstract description 40
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims abstract description 40
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 8
- 125000005843 halogen group Chemical group 0.000 claims description 56
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 19
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 229910052736 halogen Chemical group 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000011594 Autoinflammatory disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 229910020008 S(O) Inorganic materials 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 19
- 201000010099 disease Diseases 0.000 abstract description 17
- 230000005764 inhibitory process Effects 0.000 abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 44
- -1 more particularly Chemical group 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 0 [1*]CC1=CC(S(=O)(=O)CC)=CN=C1N1CCC(*C2=CC=CC=C2)CC1.[3*]C Chemical compound [1*]CC1=CC(S(=O)(=O)CC)=CN=C1N1CCC(*C2=CC=CC=C2)CC1.[3*]C 0.000 description 17
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 102000043136 MAP kinase family Human genes 0.000 description 7
- 108091054455 MAP kinase family Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000007863 steatosis Effects 0.000 description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108010006654 Bleomycin Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 6
- 229960001561 bleomycin Drugs 0.000 description 6
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 6
- 229940125898 compound 5 Drugs 0.000 description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 6
- 229960002591 hydroxyproline Drugs 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 230000003176 fibrotic effect Effects 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 5
- 229960003073 pirfenidone Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- LKVFCSWBKOVHAH-UHFFFAOYSA-N 4-Ethoxyphenol Chemical compound CCOC1=CC=C(O)C=C1 LKVFCSWBKOVHAH-UHFFFAOYSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 description 4
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 4
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 4
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000001847 surface plasmon resonance imaging Methods 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229950001279 elafibranor Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 108700016226 indium-bleomycin Proteins 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 3
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- CKEHZBXHXCACMG-UHFFFAOYSA-N 2,3-dichloro-5-methylsulfonylpyridine Chemical compound CS(=O)(=O)C1=CN=C(Cl)C(Cl)=C1 CKEHZBXHXCACMG-UHFFFAOYSA-N 0.000 description 2
- JNYKOGUXPNAUIB-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-5-ol Chemical compound OC1=CC=C2OCCC2=C1 JNYKOGUXPNAUIB-UHFFFAOYSA-N 0.000 description 2
- MSUQCJKXHIGCMN-UHFFFAOYSA-N 5,6-dichloropyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CN=C(Cl)C(Cl)=C1 MSUQCJKXHIGCMN-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- CEULQDQXXQXBSA-UHFFFAOYSA-N CC1=CC=C(OC2=CC(S(=O)(=O)N(C)C)=CN=C2N2CCC(OC3=CN=C(C(N)=O)C=C3)CC2)C=C1.CCOC1=CC=C(OC2=CC(S(=O)(=O)N(C)C)=CN=C2N2CCC(OC3=CC=C(Cl)C=C3)CC2)C=C1.CCOC1=CC=C(OC2=CC(S(=O)(=O)N(C)C)=CN=C2N2CCC(OC3=CN=C(C(N)=O)C=C3)CC2)C=C1.CCOC1=CC=C(OC2=CC(S(C)(=O)=O)=CN=C2N2CCC(OC3=CC=C(Cl)C=C3)CC2)C=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CN=C(C(N)=O)C=C3)CC2)C(OC2=CC3=C(C=C2)OCC3)=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CN=C(C(N)=O)C=C3)CC2)C(OC2=CC=C(OC(F)(F)F)C=C2)=C1 Chemical compound CC1=CC=C(OC2=CC(S(=O)(=O)N(C)C)=CN=C2N2CCC(OC3=CN=C(C(N)=O)C=C3)CC2)C=C1.CCOC1=CC=C(OC2=CC(S(=O)(=O)N(C)C)=CN=C2N2CCC(OC3=CC=C(Cl)C=C3)CC2)C=C1.CCOC1=CC=C(OC2=CC(S(=O)(=O)N(C)C)=CN=C2N2CCC(OC3=CN=C(C(N)=O)C=C3)CC2)C=C1.CCOC1=CC=C(OC2=CC(S(C)(=O)=O)=CN=C2N2CCC(OC3=CC=C(Cl)C=C3)CC2)C=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CN=C(C(N)=O)C=C3)CC2)C(OC2=CC3=C(C=C2)OCC3)=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CN=C(C(N)=O)C=C3)CC2)C(OC2=CC=C(OC(F)(F)F)C=C2)=C1 CEULQDQXXQXBSA-UHFFFAOYSA-N 0.000 description 2
- MTMDBLRLLIBFDU-UHFFFAOYSA-N CCCOC1=CC=C(NC2=CC(S(=O)(=O)N(C)C)=CN=C2N2CCN(CC3=CC=C(Cl)C=C3)CC2)C=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CC=C(Cl)C=C3)CC2)C(C2=CC3=C(C=C2)OCC3)=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CC=C(Cl)C=C3)CC2)C(NC2=CC3=C(C=C2)OC(CO)=C3)=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CC=C(Cl)C=C3)CC2)C(NC2=CC3=C(C=C2)OCC3)=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CC=C(Cl)C=C3)CC2)C(NC2=CC3=C(C=C2)OCO3)=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CC=C(Cl)C=C3)CC2)C(OC2=CC3=C(C=C2)OCC3)=C1 Chemical compound CCCOC1=CC=C(NC2=CC(S(=O)(=O)N(C)C)=CN=C2N2CCN(CC3=CC=C(Cl)C=C3)CC2)C=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CC=C(Cl)C=C3)CC2)C(C2=CC3=C(C=C2)OCC3)=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CC=C(Cl)C=C3)CC2)C(NC2=CC3=C(C=C2)OC(CO)=C3)=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CC=C(Cl)C=C3)CC2)C(NC2=CC3=C(C=C2)OCC3)=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CC=C(Cl)C=C3)CC2)C(NC2=CC3=C(C=C2)OCO3)=C1.CN(C)S(=O)(=O)C1=CN=C(N2CCC(OC3=CC=C(Cl)C=C3)CC2)C(OC2=CC3=C(C=C2)OCC3)=C1 MTMDBLRLLIBFDU-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 2
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 108010034143 Inflammasomes Proteins 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 102000046157 human CSF2 Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002310 reflectometry Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 231100000161 signs of toxicity Toxicity 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WYXQQAYIAJRORT-UHFFFAOYSA-N 1-benzofuran-5-ylboronic acid Chemical compound OB(O)C1=CC=C2OC=CC2=C1 WYXQQAYIAJRORT-UHFFFAOYSA-N 0.000 description 1
- ZHKJHQBOAJQXQR-UHFFFAOYSA-N 1H-azirine Chemical compound N1C=C1 ZHKJHQBOAJQXQR-UHFFFAOYSA-N 0.000 description 1
- SCEIUGQQBYRBPP-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-azepine Chemical compound C1CCC=CNC1 SCEIUGQQBYRBPP-UHFFFAOYSA-N 0.000 description 1
- YJMADHMYUJFMQE-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-5-amine Chemical compound NC1=CC=C2OCCC2=C1 YJMADHMYUJFMQE-UHFFFAOYSA-N 0.000 description 1
- BEWVAZNECYSPMT-UHFFFAOYSA-N 2,3-dihydro-1h-azepine Chemical compound C1CC=CC=CN1 BEWVAZNECYSPMT-UHFFFAOYSA-N 0.000 description 1
- LELTYNIPRLOYCM-UHFFFAOYSA-N 4-(4-chlorophenoxy)piperidin-1-ium;chloride Chemical compound Cl.C1=CC(Cl)=CC=C1OC1CCNCC1 LELTYNIPRLOYCM-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- NMMFHPWVBDVMFL-UHFFFAOYSA-N 4-piperidin-4-yloxypyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC(OC2CCNCC2)=C1 NMMFHPWVBDVMFL-UHFFFAOYSA-N 0.000 description 1
- YWDJEAXGCYRJIM-UHFFFAOYSA-N 5,6-dichloro-n,n-dimethylpyridine-3-sulfonamide Chemical compound CN(C)S(=O)(=O)C1=CN=C(Cl)C(Cl)=C1 YWDJEAXGCYRJIM-UHFFFAOYSA-N 0.000 description 1
- WJVOBXJACCZXSS-UHFFFAOYSA-N 5-chloro-6-[4-(4-chlorophenoxy)piperidin-1-yl]-N,N-dimethylpyridine-3-sulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC(=C(N=C1)N2CCC(CC2)OC3=CC=C(C=C3)Cl)Cl WJVOBXJACCZXSS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 238000007125 Buchwald synthesis reaction Methods 0.000 description 1
- QAGXDEXWTAMVQY-UHFFFAOYSA-N CS(C(C=C1Cl)=CN=C1N(CC1)CCC1OC(C=C1)=CC=C1Cl)(=O)=O Chemical compound CS(C(C=C1Cl)=CN=C1N(CC1)CCC1OC(C=C1)=CC=C1Cl)(=O)=O QAGXDEXWTAMVQY-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101100023496 Homo sapiens MAPK8 gene Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000022553 Parenchymal lung disease Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102000007156 Resistin Human genes 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 108010001122 alpha(2)-microglobulin Proteins 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 1
- YRTMEEURRDTMST-UHFFFAOYSA-N diazetidine Chemical compound C1CNN1 YRTMEEURRDTMST-UHFFFAOYSA-N 0.000 description 1
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 description 1
- KJGHYQZXEYTDSW-UHFFFAOYSA-N diazocane Chemical compound C1CCCNNCC1 KJGHYQZXEYTDSW-UHFFFAOYSA-N 0.000 description 1
- IWMMXPNBCHCFCY-UHFFFAOYSA-M dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;palladium(2+);2-phenylethanamine;chloride Chemical compound [Pd+]Cl.NCCC1=CC=CC=[C-]1.COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 IWMMXPNBCHCFCY-UHFFFAOYSA-M 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- HGGNZMUHOHGHBJ-UHFFFAOYSA-N dioxepane Chemical compound C1CCOOCC1 HGGNZMUHOHGHBJ-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- KUSGATRNQCYALG-UHFFFAOYSA-N dithiepane Chemical compound C1CCSSCC1 KUSGATRNQCYALG-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000019189 interleukin-1 beta production Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- OXUZCBDDXOMZAM-UHFFFAOYSA-N oxathiepane Chemical compound C1CCOSCC1 OXUZCBDDXOMZAM-UHFFFAOYSA-N 0.000 description 1
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 description 1
- XHWNEBDUPVMPKI-UHFFFAOYSA-N oxazetidine Chemical compound C1CON1 XHWNEBDUPVMPKI-UHFFFAOYSA-N 0.000 description 1
- OZQGLZFAWYKKLQ-UHFFFAOYSA-N oxazinane Chemical compound C1CCONC1 OZQGLZFAWYKKLQ-UHFFFAOYSA-N 0.000 description 1
- KKHNAVZYZJMXFV-UHFFFAOYSA-N oxazocane Chemical compound C1CCCONCC1 KKHNAVZYZJMXFV-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- PGAZQSBUJDVGIX-UHFFFAOYSA-N thiazepane Chemical compound C1CCNSCC1 PGAZQSBUJDVGIX-UHFFFAOYSA-N 0.000 description 1
- AJZGFFKDLABHDD-UHFFFAOYSA-N thiazinane Chemical compound C1CCSNC1 AJZGFFKDLABHDD-UHFFFAOYSA-N 0.000 description 1
- VZYZKDFMQQEERI-UHFFFAOYSA-N thiazocane Chemical compound C1CCCSNCC1 VZYZKDFMQQEERI-UHFFFAOYSA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 1
- 229930004006 tropane Natural products 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- the present invention relates to a novel class of pyridine-sulfonamide compounds and to compositions comprising the same.
- the compounds and compositions (such as pharmaceutical compositions) of the present invention can be used as medicaments in the treatment of diseases related to interleukin 1 beta (IL-1 ⁇ ) such as inflammatory and fibrotic diseases.
- IL-1 ⁇ interleukin 1 beta
- IL-1 has been shown to be involved in a wide range of human pathologies ranging from autoinflammatory diseases to rheumatoid arthritis, IL-1-blocking agents (IL-1Ra, Anakinra; anti-IL-1b monoclonal antibody [mAb], Canakinumab; and anti-IL-1a, MABp1) have been approved for clinical use or are being evaluated in some of these disorders (Dinarello, 2009; Gabay et al., 2010; Garlanda et al., 2013; Udalova et al., 2016).
- IL-1Ra Anakinra
- mAb monoclonal antibody
- MABp1 anti-IL-1a, MABp1
- IL-1 has long been associated with inflammation and innate immunity. It is now apparent that this cytokine plays differential roles in shaping and orienting innate immunity and inflammation in response to different microbial or environmental challenges. Moreover, during the last decade the preclinical research on the role of IL-1 beta (IL-1 ⁇ ) has extended beyond classic inflammation to understand its role in immunopathology, fibrotic disease, degenerative disease, cardiovascular disease and cancer.
- the production and subsequent secretion of IL-1 ⁇ depends mainly on the activation of the toll-like receptor 4 (TLR4) and the inflammasome.
- TLR4 toll-like receptor 4
- an inflammatory stimuli or an infection, signaling through the TLR4 receptor triggers pro-IL-1 ⁇ production; in a second step the inflammasome-activated caspase-1 proteolytically releases IL-1 ⁇ into the bloodstream.
- This cytokine is responsible for the activation of T cells as well as antigen recognition, among other important functions.
- the production of IL-1 ⁇ depends on the action of mitogen-activated protein kinase (MAPK), a group of proteins within the signaling route of TLR4 receptors.
- MAPK mitogen-activated protein kinase
- MAPK such as p38, JNK and ERK activate nuclear factors that bind to gene promoters related to the production of IL-1 ⁇ .
- the inhibition of MAPK is a valid approach to avoid production of IL-1 ⁇ in the context of inflammatory diseases and conditions.
- NASH Non-alcoholic Steatohepatitis
- IPF Idiopathic Pulmonary Fibrosis
- NASH Non-Alcoholic Steatohepatitis
- non-alcoholic fatty liver disease is a common hepatic disorder with histological features of alcohol-induced fatty liver disease in individuals who consume little or no alcohol (Yeh M et al., 2007; Marchesini G et al., 2003).
- NAFLD is due to the abnormal retention of lipids within cells (commonly defined as steatosis), an event more frequent in liver since this organ is primarily responsible of lipid metabolism.
- NAFLD has a spectrum of histological forms including hepatic steatosis, and non-alcoholic steatohepatitis (NASH), which is characterized by liver inflammation, steatosis, necrosis and fibrosis due to the disruption of liver cells.
- liver biopsy remains the gold standard for evaluating liver fibrosis, but this method of analysis could not be done for every single study due to its invasiveness.
- Non-invasive evaluation of liver biochemistry and metabolism is often used to define liver diseases, such as in NAFLD and NASH (Gressner A et al., 2009, World J Gastroenterol; 15: 2433-2440; Vuppalanchi R and Chalasani N, 2009, Hepatology; 49: 306-317).
- AAT Alanine aminotransferase
- ASAT Aspartate aminotransfersase
- AP Alkaline Phosphatase
- GTT Gamma Glutamyl Transpeptidase
- haptoglobin total bilirubin
- alpha-2-microglobulin alpha-2-microglobulin
- Resistin cleaved or intact cytokeratin-18
- c-Jun expression correlates with disease progression from steatosis to NASH (Schulien et al, 2019, Cell Death & Differentiation; 26; 1688-1699). It has also been shown that JNK1 knockout mice are resistant to diet-induced steatohepatitis and liver fibrosis and that JNK1 contributes to the development of liver fibrosis by inducing chronic inflammation (Kodama et al., 2009, Gastroenterology; 137(4); 1467-1477).
- Murine animal models have been developed as preclinical in vivo models for NASH (Hansen H et al., 2017, Drug Discovery Today, 22: 1707-1718). C57BL/6 mice are the most frequently used as it is sensitive to a high-fat diet and develops many of the same symptoms observed in human NASH. It is furthermore known that injection of streptozotocin sensitizes mice models to high-fat diets in developing NASH.
- IPF Idiopathic Pulmonary Fibrosis
- Idiopathic pulmonary fibrosis is an interstitial lung disease characterised by chronic inflammation and subsequent progressive scarring of the lungs.
- the interstitial lung diseases (ILDs) are a heterogeneous group of parenchymal lung diseases characterised by varying degrees of inflammation and fibrosis. Some of these may occur secondary to a known precipitant such as drugs, autoimmune connective tissue disease, hypersensitivity to inhaled organic antigens, or sarcoidosis, whilst others, the idiopathic interstitial pneumonias (IIPs), have no identifiable cause.
- Idiopathic pulmonary fibrosis is one of the most aggressive forms of IIP, characterised by chronic, progressive fibrosis associated with inexorable decline in lung function, progressive respiratory failure, and high mortality (Shaney et al., 2018).
- Elevated levels of IL-1 ⁇ are known to contribute to proinflammatory and pro-fibrotic environment in lungs of patients suffering from idiopathic pulmonary fibrosis (IPF) (Barlo et al., 2011)
- IPF idiopathic pulmonary fibrosis
- animal models of lung fibrosis showed that transient expression of IL-1 ⁇ induces acute lung injury and chronic repair leading to pulmonary fibrosis (Kolb M., 2001; Gasse P et al., 2011).
- liver disorders and other fibrotic disorders in particular those involving liver and lung fibrosis, is still clear and urgent.
- the present invention provides a novel class of compounds having Formula I and/or Formula Ia, which includes pharmaceutically acceptable salts thereof.
- the compounds of the invention are intended for the treatment of diseases responsive to inhibition of IL-1 ⁇ such as non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
- NASH non-alcoholic steatohepatitis
- IPF idiopathic pulmonary fibrosis
- the compounds of the present invention are compounds of Formula I or pharmaceutically acceptable salts thereof:
- R 1 is an aromatic or heteroaromatic ring system optionally substituted with one or two substituents selected from the group consisting of C 1-4 alkyl-Y 1 —, C 2-4 alkenyl-Y 1 —, C 2-4 alkynyl-Y 1 —, C 1-4 alkyl-Y 1 — substituted with halo, such as fluoro, C 2-4 alkenyl-Y 1 — substituted with halo, C 2-4 alkynyl-Y 1 substituted with halo, HO—C 1-4 alkanediyl-Y 1 —, HO—C 2-4 alkenediyl-Y 1 —, HO—C 2-4 alkynediyl-Y 1 —, HO—C 1-4 alkanediyl-, HO—C 2-4 alkenediyl-, HO—C 2-4 alkynediyl-, C 1-4 alkyl-C 2-4 alkenyl-, C 2-4 alky
- X 1 is NH, O, or CH 2 ;
- n1 is 0 or 1
- X 3 is absent or NR y ;
- R x and R y are independently C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, or H, such as CH 3 or H;
- L is O, S, S(O), S(O) 2 , NH, C(O), or CH 2 ;
- Z 1 , Z 2 , and Z 3 are independently selected from N and CH;
- R 3 is selected from the group consisting of H, halo, C(O)NR 2a R 2b , C(O)OR 2a , OR 2a , NR 2a R 2b , OC(O)R 2a , NR 2a C(O)R 2b , C 1-4 alkyl optionally substituted with one or more halo, C 2-4 alkenyl optionally substituted with one or more halo, and C 2-4 alkynyl optionally substituted with one or more halo, wherein R 2a and R 2b are independently selected from the group consisting of H, C 1-4 alkyl, C 2-4 alkenyl, and C 2-4 alkynyl.
- the present invention concerns a pharmaceutical composition
- a pharmaceutical composition comprising a compound according to the present invention and a pharmaceutically acceptable excipient or carrier.
- the present invention concerns the compound according to the present invention or the composition according to the present invention for use as a medicament.
- the present invention concerns the compound according to the present invention or the composition according to the present invention for use in the treatment of diseases responsive to inhibition of IL-1 ⁇ , such as non-alcoholic steatoheptatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
- diseases responsive to inhibition of IL-1 ⁇ such as non-alcoholic steatoheptatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
- FIG. 1 Effect of Compound 5 and Compound 7 on NAFLD activity score (NAS).
- NAS NAFLD activity score
- FIG. 2 Serum AST (U/L) levels after 28 days of treatment.
- FIG. 3 Effect of Compound 5 and 7 on the liver to body weight ratio.
- FIG. 4 Effect of Compound 7 on lung hydroxyproline levels in the treatment of bleomycin-induced IPF.
- FIG. 5A Total Cell Counts in BALF.
- FIG. 5B Differential Leukocyte Counts in BALF.
- FIG. 6A H&E Ashcroft Score.
- FIG. 6B % Collagen Proportion Area (CPA).
- C 1-4 alkyl is intended to mean a linear or branched hydrocarbon group having 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl.
- C 2-4 alkenyl is intended to cover linear or branched hydrocarbon groups having 2 to 4 carbon atoms and comprising a double bond.
- alkenyl groups are vinyl, allyl, and butenyl.
- Preferred examples of alkenyl are vinyl and allyl, especially allyl.
- C 2-4 alkynyl is intended to mean a linear or branched hydrocarbon group having 2 to 4 carbon atoms and containing a triple bond.
- Illustrative examples of C 2-4 alkynyl groups include acetylene, propynyl, butynyl, as well as branched forms of these.
- the position of unsaturation may be at any position along the carbon chain. More than one bond may be unsaturated such that the “C 2-4 alkynyl” is a di-yne as is known to the person skilled in the art.
- halo or “halogen” includes fluoro, chloro, bromo, and iodo, more particularly, fluoro, chloro and bromo.
- aromatic ring or ring system is intended to mean a fully or partially aromatic carbocyclic ring or ring system, such as phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracyl, phenanthracyl, pyrenyl, benzopyrenyl, fluorenyl and xanthenyl.
- heteromatic ring or ring system is intended to mean a fully or partially aromatic carbocyclic ring or ring system where one or more of the carbon atoms have been replaced with heteroatoms, e.g. nitrogen ( ⁇ N- or —NH—), sulphur, and/or oxygen atoms.
- heteroaromatic ring or ring system groups examples include oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, coumaryl, furyl, thienyl, quinolyl, benzothiazolyl, benzotriazolyl, benzodiazolyl, benzooxozolyl, phthalazinyl, phthalanyl, triazolyl, tetrazolyl, isoquinolyl, acridinyl, carbazolyl, dibenzazepinyl, indolyl, benzopyrazolyl, phenoxazonyl, benzofuranyl, dihydrobenzofuranyl and benzodioxolyl.
- heterocyclic ring or ring system is intended to mean a non-aromatic carbocyclic ring or ring system where one or more of the carbon atoms have been replaced with heteroatoms, e.g. nitrogen ( ⁇ N- or —NH—), sulphur, and/or oxygen atoms.
- heterocyclic groups examples include imidazolidine, piperazine, hexahydropyridazine, hexahydropyrimidine, diazepane, diazocane, pyrrolidine, piperidine, azepane, azocane, aziridine, azirine, azetidine, pyroline, tropane, oxazinane (morpholine), azepine, dihydroazepine, tetrahydroazepine, hexahydroazepine, oxazolane, oxazepane, oxazocane, thiazolane, thiazinane, thiazepane, thiazocane, oxazetane, diazetane, thiazetane, tetrahydrofuran, tetrahydropyran, oxepane, tetrahydrothiophene, tetrahydrothi
- the term “optionally substituted” is intended to mean that the group in question may be substituted one or more times, preferably 1-2 times. Furthermore, the term “optionally substituted” may also mean that the group in question is unsubstituted.
- the compounds of the present invention can be in a free form or in the form of a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt is to be understood as a salt formed with either a base or an acid, wherein the resulting counter-ion does not significantly add to the toxicity of the compound of the present invention.
- Examples of pharmaceutically acceptable salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate or hydrobromide, etc., organic acid salts such as acetate, fumarate, oxalate, citrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate or maleate, etc. Also, when the compound has a substituent such as carboxyl group, there may be mentioned a salt with a base (for example, alkali metal salt such as sodium salt, potassium salt, etc. or alkaline earth metal salt such as calcium salt, etc.).
- a base for example, alkali metal salt such as sodium salt, potassium salt, etc. or alkaline earth metal salt such as calcium salt, etc.
- the compounds of the invention are compounds of Formula I or pharmaceutically acceptable salts thereof:
- R 1 is an aromatic or heteroaromatic ring system optionally substituted with one or two substituents selected from the group consisting of C 1-4 alkyl-Y 1 —, C 2-4 alkenyl-Y 1 —, C 2-4 alkynyl-Y 1 —, C 1-4 alkyl-Y 1 — substituted with halo, such as fluoro, C 2-4 alkenyl-Y 1 — substituted with halo, C 2-4 alkynyl-Y 1 substituted with halo, HO—C 1-4 alkanediyl-Y 1 —, HO—C 2-4 alkenediyl-Y 1 —, HO—C 2-4 alkynediyl-Y 1 —, HO—C 1-4 alkanediyl-, HO—C 2-4 alkenediyl-, HO—C 2-4 alkynediyl-, C 1-4 alkyl- C 2-4 alkenyl-, C 2-4 alky
- Y 1 is selected from the group consisting of O, S, NH, C(O), C(O)O, C(O)NH, O(CO) and NHC(O);
- X 1 is NH, O, or CH 2 ;
- n1 is 0 or 1
- X 3 is absent or NR y ;
- R x and R y are independently C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, or H, such as CH 3 or H;
- L is O, S, S(O), S(O) 2 , NH, C(O), or CH 2 ;
- Z 1 , Z 2 , and Z 3 are independently selected from N and CH;
- R 3 is selected from the group consisting of H, halo, C(O)NR 2a R 2b , C(O)OR 2a , OR 2a , NR 2a R 2b , OC(O)R 2a , NR 2a C(O)R 2b , C 1-4 alkyl optionally substituted with one or more halo, C 2-4 alkenyl optionally substituted with one or more halo, and C 2-4 alkynyl optionally substituted with one or more halo, wherein R 2a and R 2b are independently selected from the group consisting of H, C 1-4 alkyl, C 2-4 alkenyl, and C 2-4 alkynyl.
- the compound of formula I is a compound having the formula Ia:
- R 1 is selected from the group consisting of C 1-4 alkyl-Y 1 —, C 2-4 alkenyl-Y 1 —, C 2-4 alkynyl-Y 1 —, C 1-4 alkyl-Y 1 — substituted with halo, such as fluoro, C 2-4 alkenyl-Y 1 -substituted with halo, C 2-4 alkynyl-Y 1 substituted with halo, HO—C 1-4 alkanediyl-Y 1 —, HO—C 2-4 alkenediyl-Y 1 —, HO—C 2-4 alkynediyl-Y 1 —, HO—C 1-4 alkanediyl-, HO—C 2-4 alkenediyl-, HO—C 2-4 alkynediyl-, C 1-4 alkyl- C 2-4 alkenyl-, C 2-4 alkynyl-, C 1-4 alkyl substituted with halo,
- R 2 is hydrogen
- R 1 together with R 2 forms an aromatic, heteroaromatic, cyclic or heterocyclic five- or six-membered ring optionally substituted with one or two substituents selected from the group consisting of C 1-4 alkyl-Y 1 —, C 2-4 alkenyl-Y 1 —, C 2-4 alkynyl-Y 1 —, C 1-4 alkyl-Y 1 — substituted with halo, such as fluoro, C 2-4 alkenyl-Y 1 — substituted with halo, C 2-4 alkynyl-Y 1 substituted with halo, HO—C 1-4 alkanediyl-, HO—C 2-4 alkenediyl-, HO—C 2-4 alkynediyl-, C 1-4 alkyl- C 2-4 alkenyl-, C 2-4 alkynyl-, C 1-4 alkyl substituted with halo, C 2-4 alkenyl- substituted with halo, C 2-4 alky
- X 1 , n1, Y 1 , X 3 , R x , R y , L, Z 1 , Z 2 , Z 3 , R 3 are as defined for the compound of formula I.
- X 3 is NR y , giving rise to the compounds of formula II and Ha:
- X 1 , n1, Y 1 , R x , R y , L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , R 3 are as defined for the compounds of formula I and formula Ia.
- R 3 is in the para position, giving rise to the compounds of formula III and IIIa:
- X 1 , n1, Y 1 , R x , R y , L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , R 3 are as defined for the compounds of formula I and formula Ia.
- Z 2 is CH, giving rise to the compounds of formula IV and IVa:
- X 1 , n1, Y 1 , R x , R y , L, Z 1 , Z 3 , R 1 , R 2 , R 3 are as defined for the compounds of formula I and formula Ia.
- Y 1 is selected from the group consisting of O, S, NH, C(O), and C(O)NH. In a further embodiment, Y 1 is selected from the group consisting of O, S, and NH. In yet a further embodiment, Y 1 is O.
- X 1 is NH or O. In yet another embodiment, X 1 is NH or O and n1 is 1.
- R x and R y are independently C 1-4 alkyl. In yet a further embodiment, R x and R y are methyl.
- L is selected from the group consisting of O, S, and CH 2 . In another embodiment, L is selected from the group consisting of O and CH 2 . In still another embodiment, L is O.
- Z 1 is CH. In still a further embodiment, Z 1 is CH and L is O. In yet a further embodiment, Z 1 is CH, Z 2 is CH, and L is O.
- R 3 is selected from the group consisting of H, halo, and C(O)NH 2 . In still another embodiment, R 3 is selected from the group consisting of halo and C(O)NH 2 . In yet another embodiment, R 3 is selected from the group consisting of Cl and C(O)NH 2 . In a further embodiment, R 3 is Cl.
- R 2 is H.
- the compounds of formula IVa have the following formula V:
- X 1 , Y 1 , R x , R y , R 1 , and R 3 are as defined for the compounds of formula I and formula Ia.
- X 1 is O
- R 1 is C 1-4 alkyl-O—
- R 3 is halo or C(O)NH 2
- R x and R y are independently C 1-4 alkyl.
- the compound according to the present invention is selected from the group consisting of:
- the compounds of the present invention are intended for use as a medicament.
- the compounds of the invention may in principle be applied on their own, but they are preferably formulated with a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier is an inert carrier suitable for each administration method, and can be formulated into conventional pharmaceutical preparation (tablets, granules, capsules, powder, solution, suspension, emulsion, injection, infusion, etc.).
- a carrier there may be mentioned, for example, a binder, an excipient, a lubricant, a disintegrant and the like, which are pharmaceutically acceptable.
- they When they are used as an injection solution or an infusion solution, they can be formulated by using distilled water for injection, physiological saline, an aqueous glucose solution.
- the administration method of the compounds of the present invention is not particularly limited, and a usual oral or parenteral administration method (intravenous, intramuscular, subcutaneous, percutaneous, intranasal, transmucosal, enteral, etc.) can be applied.
- a usual oral or parenteral administration method intravenous, intramuscular, subcutaneous, percutaneous, intranasal, transmucosal, enteral, etc.
- the dosage of the tetrahydroisoquinoline derivatives or a pharmaceutically acceptable salt thereof of the present invention may optionally be set in a range of an effective amount sufficient for showing a pharmacological effect, in accordance with the potency or characteristics of the compound to be used as an effective ingredient.
- the dosage may vary depending on administration method, age, body weight or conditions of a patient.
- the compounds of the invention are intended for the treatment of diseases responsive to inhibition of IL-1 ⁇ such as non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
- diseases responsive to inhibition of IL-1 ⁇ such as non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
- NASH non-alcoholic steatohepatitis
- IPF idiopathic pulmonary fibrosis
- the disease responsive to inhibition of IL-1 ⁇ is selected from the group consisting of non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), auto-inflammatory diseases, cardiovascular diseases, osteoarthritis, lung cancer and gout.
- NASH non-alcoholic steatohepatitis
- IPF idiopathic pulmonary fibrosis
- auto-inflammatory diseases cardiovascular diseases, osteoarthritis, lung cancer and gout.
- the disease is NASH.
- the disease is IPF.
- substituted pyridine-sulfonamides of formula II and IIa of the present invention are generally prepared via intermediate C, which is prepared as outlined in Scheme 1:
- intermediate C may require additional synthetic transformations, such as protection/de-protection reactions, from those described in Scheme 1.
- the compounds according to the invention may be prepared according to Schemes 2b, 2c, or 2d.
- a screw-cap test-tube equipped with a magnetic stir bar, was charged with BrettPhos-precatalyst (4 mol %), 2,3-dihydrobenzo[b]furan-5-amine (1 eq.) and the intermediate compound obtained in Example 2 (1 eq.).
- the vial was sealed with a teflon screw-cap, evacuated and backfilled with nitrogen; this procedure was repeated two additional times.
- LiHMDS (1M in THF, 2.5 eq.
- the reaction mixture was stirred at 40° C. until reaction was completed (2.5 h).
- the solution was allowed to cool to room temperature, quenched by the addition of aqueous, saturated NH 4 Cl solution (5 mL) and then diluted with EtOAc.
- Example 12 In Vitro Inhibition of IL-1 ⁇ in Human Primary Macrophages Challenged with LPS
- RPMI 1640 basal medium was prepared according to the manufacturer's instructions on the data sheet. A sterility check was carried out using 5 mL of medium for 48 hours at 37° C. incubator with constant supply of 5% CO 2 . Following the sterility check, the basal medium was made complete by addition of FBS and Pen/Strep antibiotic. The medium was stored at 4° C. until further use.
- a single sachet of PBS was dissolved in a litre of Milli-Q water. PBS was filtered through a 0.22 ⁇ m filter membrane and stored at 4° C. until further use.
- PBMC Peripheral Blood Mononuclear Cells
- a pasteur pipette was used to aspirate the upper layer to within 0.5 cm of the opaque interface containing the mononuclear cells. The upper layer was discarded. With a Pasteur pipette, the opaque interface was carefully transferred to a clean conical centrifuge tube. 5 mL RPMI was added to the tube and mixed by inversion, followed by centrifugation at 250 ⁇ g for exactly 10 minutes. The supernatant was aspirated and discarded.
- the leukocyte pellet was re-suspended with 5 mL RPMI and mixed gently with a Pasteur pipette, followed by centrifugation at 250 ⁇ g for exactly 10 minutes. The pellet was washed 3 X with PBS and re-suspended in RPMI medium.
- the number of viable PBMCs/mL was counted.
- PBMC suspension 10 ⁇ L was diluted with 90 ⁇ L of PBS medium (1:10 dilution). 20 ⁇ L of cell suspension was added to 20 ⁇ L of trypan blue solution (1:1 ratio) and was mixed carefully to avoid aerosol formation. A haemocytometer was loaded with cell culture mixture until the area under the coverslip was sufficiently filled. The suspension was allowed to settle in the haemocytometer for at least 10 seconds before counting.
- the viable cells were counted in four corner 1 mm squares of one chamber, as well as the number of dead cells. Viable PBMCs are clear; non-viable PBMCs are blue. Cells that touched either the top line or vertical perimeter line of any corner square were included. Cells that touched either the bottom line or right vertical perimeter line of any corner square were not counted.
- PBMC/mL PBMC in all four squares ⁇ 10 ⁇ 2 ⁇ 10 4 /4
- Total cell count PBMC/mL ⁇ Total volume (mL) of PBMC suspension
- % Cell viability (Number of viable cells counted/total number of cells counted (viable+dead)) ⁇ 100
- PBMCs 2 ⁇ 10 5 PBMCs at a total volume of 200 ⁇ L/well were plated into a 96-well plate and incubated for 4 hrs at 37° C. in a CO 2 incubator to allow the monocytes to settle, leaving the lymphocytes in suspension. Following incubation, 100 ⁇ L were aspirated out of each well to ensure removal of the lymphocyte population.
- the monocytes were differentiated to macrophages by addition of 200 ng/mL of recombinant human GM-CSF (4 mg/mL stock) and incubated at 37° C./5% CO 2 for 6 days.
- the medium was changed every two days by removing half the volume of medium in the well and re-supplementing with fresh RPMI complete medium and recombinant human GM-CSF.
- the cells were treated in duplicates with a compound according to the invention in a total volume of 50 ⁇ L, maintaining a final DMSO percentile of 0.5%.
- the plate was transferred to an incubator maintained at 37° C./5% CO 2 for 2 hours.
- the cells were stimulated with 100 ng/mL of LPS (4 ⁇ ) (1 mg/mL stock) in a total volume of 50 ⁇ L.
- the plate was transferred to an incubator maintained at 37° C./5% CO 2 for 16 hours.
- % Cytotoxicity 100 ⁇ (100*(Average Test Compound Counts ⁇ Average Negative Control Counts)/(Average Positive Control Counts ⁇ Average Negative Control Counts))
- the chip was then blocked with 5% (w/v) non-fat milk in water overnight, and washed with 10 ⁇ PBST for 10 min, lx PBST for 10 min, and deionized water twice for 10 min before being dried under a stream of nitrogen prior to use.
- SPRi Surface Plasmon Resonance Imaging
- Each measurement cycle contained four steps: washing with PBST running buffer at a constant rate of 2 ⁇ L/s to obtain a stable baseline, sample injection at 5 ⁇ L/s for binding, surface washing with PBST at 2 ⁇ L/s for 300 s, and regeneration with 0.5% (v/v) H 3 PO 4 at 2 ⁇ L/s for 300 s. All the measurements were performed at 4° C.
- the signal changes after binding and washing were recorded in AU as the assay value.
- Selected protein-grafted regions in the SPR images were analyzed, and the average reflectivity variations of the chosen areas were plotted as a function of time.
- Real-time binding signals were recorded and analyzed by Data Analysis Module (DAM, Plexera Bioscience, Seattle, Wash., US).
- DAM Data Analysis Module
- Kinetic analysis was performed using BIAevaluation 4.1 software (Biacore, Inc.).
- the chip was then blocked with 5% (w/v) non-fat milk in water overnight, and washed with 10 ⁇ PBST for 10 min, lx PBST for 10 min, and deionized water twice for 10 min before being dried under a stream of nitrogen prior to use.
- SPRi Surface Plasmon Resonance Imaging
- Each measurement cycle contained four steps: washing with PBST running buffer at a constant rate of 2 ⁇ L/s to obtain a stable baseline, sample injection at 5 ⁇ L/s for binding, surface washing with PBST at 2 ⁇ L/s for 300 s, and regeneration with 0.5% (v/v) H 3 PO 4 at 2 ⁇ L/s for 300 s. All the measurements were performed at 4° C.
- the signal changes after binding and washing are recorded as the assay value.
- Selected protein-grafted regions in the SPR images were analyzed, and the average reflectivity variations of the chosen areas were plotted as a function of time.
- Real-time binding signals were recorded and analyzed by Data Analysis Module (DAM, Plexera Bioscience, Seattle, Wash., US).
- DAM Data Analysis Module
- Kinetic analysis was performed using BIAevaluation 4.1 software (Biacore, Inc.).
- the delivered pups were subcutaneously injected on the post-natal day 2 (PND-2) with 200 ⁇ g of Streptozotocin and were allowed to remain with the mother until they reached the weanling age. After weanling, the male pups were selected and fed with 60% kcal fat diet (Research Diet-D12492) for the next 2 weeks. All the animals were observed twice daily for clinical signs.
- mice were dosed with vehicle, test compounds and reference compound (elafibranor) twice daily morning (9.00 AM) and evening before the start of dark cycle (6:00 PM) from day 0 to 28.
- Blood glucose was estimated before the treatment start and on the termination day 28. Serum ALT and AST levels were measured from the plasma before the treatment start and on day 28.
- Histopathology analysis including H&E staining, Masson's trichrome staining and Oil-Red-O (ORO) staining was performed for the liver tissues.
- Oil-Red-O stained tissue sections were examined by light microscopy in 100 ⁇ objective lens. Randomly selected five fields (approximately 688.33 ⁇ m ⁇ 922.45 ⁇ m per field) from each liver were subjected to measure stained area by using Image Pro Premier 9.1 software. The percentage of stained area was calculated by dividing lipid stained tissue area by total tissue area.
- FIG. 1 The effect of Compound 5 and Compound 7 on NAFLD activity score (NAS) is shown in FIG. 1 .
- Compound 5 at the 3 mg/kg dose significantly reduced lobular inflammation and showed a trend towards decreased steatosis and hepatic ballooning resulting in significant reduced NAS score than disease controls.
- both test compounds did not show any hepatomegaly and increase in liver to body weight ratio as shown in FIG. 3
- the delivered pups were subcutaneously injected on the post-natal day 2 (PND-2) with 1.5 U/kg of Bleomycin (intra-tracheal) and were allowed to remain with the mother until they reached the weanling age. After weanling, the male pups were selected and fed with 60% kcal fat diet (Research Diet-D12492) for the next week. All the animals were observed twice daily for clinical signs.
- mice were orally dosed with vehicle, test compounds and reference compound (Pirfenidone) twice daily morning (9.00 AM) and evening before the start of dark cycle (6:00 PM) from day 0 to 14.
- Lung hydroxyproline level was estimated before the treatment start and on the termination day 14. Total cell count and differential leukocyte count in BALF were measured before the treatment start and on day 28.
- BALF total and Differential leukocyte (macrophage and lymphocyte) counts were significantly increased in Bleomycin control group.
- Fibrosis score and % CPA were significantly increased in Bleomycin control lungs in comparison to Na ⁇ ve control.
- Compound 7 (p ⁇ 0.05) and Pirfenidone (p ⁇ 0.05) treated lung samples exhibited a significant reduction in both fibrosis score and % CPA in comparison with Bleomycin control as shown in FIGS. 6A and 6B .
- the data is in line with hydroxyproline results.
- the tested compound leads to significant improvement in lung chemistry and histological activity of IPF.
- the therapeutic profile of Compound 7 suggests that it has a potential for the treatment of human IPF. All treated animals presented body weight gain compared to Bleomycin control and had no clinical signs of toxicity or side effects.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
- The present invention relates to a novel class of pyridine-sulfonamide compounds and to compositions comprising the same. The compounds and compositions (such as pharmaceutical compositions) of the present invention can be used as medicaments in the treatment of diseases related to interleukin 1 beta (IL-1β) such as inflammatory and fibrotic diseases.
- IL-1 has been shown to be involved in a wide range of human pathologies ranging from autoinflammatory diseases to rheumatoid arthritis, IL-1-blocking agents (IL-1Ra, Anakinra; anti-IL-1b monoclonal antibody [mAb], Canakinumab; and anti-IL-1a, MABp1) have been approved for clinical use or are being evaluated in some of these disorders (Dinarello, 2009; Gabay et al., 2010; Garlanda et al., 2013; Udalova et al., 2016).
- IL-1 has long been associated with inflammation and innate immunity. It is now apparent that this cytokine plays differential roles in shaping and orienting innate immunity and inflammation in response to different microbial or environmental challenges. Moreover, during the last decade the preclinical research on the role of IL-1 beta (IL-1β) has extended beyond classic inflammation to understand its role in immunopathology, fibrotic disease, degenerative disease, cardiovascular disease and cancer. Additionally, clinical studies on the effect of blocking IL-1β(Aaron et al., 2018; Trankle C R et al., 2018; Ridker P M., 2018; Ridker P M., 2017) showed in over 10,000 patients that blocking IL-1 protected not only against atherosclerosis-driven cardiovascular mortality but also against a range of diseases including lung cancer, osteoarthritis, and gout. This finding, revealing of the diversity and yet commonality of disease mechanisms, suggests that IL-1 represents a paradigm for inflammation and immunity as well as a promising drug target (Montovani et al, 2019).
- The production and subsequent secretion of IL-1β depends mainly on the activation of the toll-like receptor 4 (TLR4) and the inflammasome. In a first step, an inflammatory stimuli or an infection, signaling through the TLR4 receptor, triggers pro-IL-1β production; in a second step the inflammasome-activated caspase-1 proteolytically releases IL-1β into the bloodstream. This cytokine is responsible for the activation of T cells as well as antigen recognition, among other important functions. Interestingly the production of IL-1β depends on the action of mitogen-activated protein kinase (MAPK), a group of proteins within the signaling route of TLR4 receptors. MAPK such as p38, JNK and ERK activate nuclear factors that bind to gene promoters related to the production of IL-1β. Thus, the inhibition of MAPK is a valid approach to avoid production of IL-1β in the context of inflammatory diseases and conditions.
- Among inflammatory diseases and conditions driven by IL-1β the Non-alcoholic Steatohepatitis (NASH) and the Idiopathic Pulmonary Fibrosis (IPF) are of great importance. These diseases are unmet clinical needs with just a few therapeutic approaches mainly focused on symptomatic treatment.
- Non-Alcoholic Steatohepatitis (NASH)
- In particular, non-alcoholic fatty liver disease (NAFLD) is a common hepatic disorder with histological features of alcohol-induced fatty liver disease in individuals who consume little or no alcohol (Yeh M et al., 2007; Marchesini G et al., 2003). NAFLD is due to the abnormal retention of lipids within cells (commonly defined as steatosis), an event more frequent in liver since this organ is primarily responsible of lipid metabolism. NAFLD has a spectrum of histological forms including hepatic steatosis, and non-alcoholic steatohepatitis (NASH), which is characterized by liver inflammation, steatosis, necrosis and fibrosis due to the disruption of liver cells.
- Hepatic imaging systems are useful to evaluate also liver structure and presence of steatosis. However, liver biopsy remains the gold standard for evaluating liver fibrosis, but this method of analysis could not be done for every single study due to its invasiveness. Non-invasive evaluation of liver biochemistry and metabolism is often used to define liver diseases, such as in NAFLD and NASH (Gressner A et al., 2009, World J Gastroenterol; 15: 2433-2440; Vuppalanchi R and Chalasani N, 2009, Hepatology; 49: 306-317). By using plasma, high level of enzymes such as Alanine aminotransferase (ALAT), Aspartate aminotransfersase (ASAT), Alkaline Phosphatase (AP), and/or Gamma Glutamyl Transpeptidase (GGT), as well as the presence of other proteins of liver origin (including haptoglobin, total bilirubin, alpha-2-microglobulin, Resistin, cleaved or intact cytokeratin-18) are commonly measured in addition to serum glucose and insulin resistance parameters.
- Means for an effective treatment for liver fibrotic diseases, and NAFLD and NASH in particular, are still insufficient. No treatment is established for patients with NASH, and several therapeutic options are tested in clinical trial (Vuppalanchi R and Chalasani N, 2009, Hepatology; 49: 306-317; Dowman J. K et al., 2009, Q J Med; 103: 71-83). These studies involve the use of many different families of chemical compounds (fibrates, thiazolidinediones, biguanides, statins, cannabinoids) and therapeutic targets (nuclear receptors, angiotensin receptors, cannabinoid receptors, HMG-CoA reductase).
- It has been shown that c-Jun expression correlates with disease progression from steatosis to NASH (Schulien et al, 2019, Cell Death & Differentiation; 26; 1688-1699). It has also been shown that JNK1 knockout mice are resistant to diet-induced steatohepatitis and liver fibrosis and that JNK1 contributes to the development of liver fibrosis by inducing chronic inflammation (Kodama et al., 2009, Gastroenterology; 137(4); 1467-1477).
- Murine animal models have been developed as preclinical in vivo models for NASH (Hansen H et al., 2017, Drug Discovery Today, 22: 1707-1718). C57BL/6 mice are the most frequently used as it is sensitive to a high-fat diet and develops many of the same symptoms observed in human NASH. It is furthermore known that injection of streptozotocin sensitizes mice models to high-fat diets in developing NASH.
- Idiopathic Pulmonary Fibrosis (IPF)
- Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic inflammation and subsequent progressive scarring of the lungs. The interstitial lung diseases (ILDs) are a heterogeneous group of parenchymal lung diseases characterised by varying degrees of inflammation and fibrosis. Some of these may occur secondary to a known precipitant such as drugs, autoimmune connective tissue disease, hypersensitivity to inhaled organic antigens, or sarcoidosis, whilst others, the idiopathic interstitial pneumonias (IIPs), have no identifiable cause. Idiopathic pulmonary fibrosis (IPF) is one of the most aggressive forms of IIP, characterised by chronic, progressive fibrosis associated with inexorable decline in lung function, progressive respiratory failure, and high mortality (Shaney et al., 2018).
- Over recent years, two novel antifibrotic therapies, pirfenidone and nintedanib, have been developed, providing treatment for many patients with IPF. Unfortunately, their profile as disease modifiers is poor and new therapeutics are needed.
- Elevated levels of IL-1β are known to contribute to proinflammatory and pro-fibrotic environment in lungs of patients suffering from idiopathic pulmonary fibrosis (IPF) (Barlo et al., 2011) In preclinical research, animal models of lung fibrosis showed that transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis (Kolb M., 2001; Gasse P et al., 2011).
- Moreover, the bleomycin-induced lung injury model of IPF has extensively demonstrated the role of IL-1β in lung fibrosis (Hoshino et al., 2009; Burgy et al., 2016).
- The role of MAPK in IPF has also been the focus of animal and human studies, concluding that activated MAPKs are significantly increased in lung homogenates from patients with IPF compared with controls (Yoshida et al., 2002). Moreover, JNK inhibition reduces lung remodelling and pulmonary fibrotic systemic markers in animal models of IPF (Van del Velden J L et al., 2016). The research results in IPF point at activated MAPK, and subsequent production of IL-1β, as one of the main drivers for IPF onset and progression.
- The need for novel therapeutic options for the management of liver disorders and other fibrotic disorders, in particular those involving liver and lung fibrosis, is still clear and urgent.
- The present invention provides a novel class of compounds having Formula I and/or Formula Ia, which includes pharmaceutically acceptable salts thereof. The compounds of the invention are intended for the treatment of diseases responsive to inhibition of IL-1β such as non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
- The compounds of the present invention are compounds of Formula I or pharmaceutically acceptable salts thereof:
- wherein
- R1 is an aromatic or heteroaromatic ring system optionally substituted with one or two substituents selected from the group consisting of C1-4 alkyl-Y1—, C2-4 alkenyl-Y1—, C2-4 alkynyl-Y1—, C1-4 alkyl-Y1— substituted with halo, such as fluoro, C2-4 alkenyl-Y1— substituted with halo, C2-4 alkynyl-Y1 substituted with halo, HO—C1-4 alkanediyl-Y1—, HO—C2-4 alkenediyl-Y1—, HO—C2-4 alkynediyl-Y1—, HO—C1-4 alkanediyl-, HO—C2-4 alkenediyl-, HO—C2-4 alkynediyl-, C1-4 alkyl-C2-4 alkenyl-, C2-4 alkynyl-, C1-4 alkyl substituted with halo, C2-4 alkenyl- substituted with halo, C2-4 alkynyl-substituted with halo, and halogen; Y1 is selected from the group consisting of O, S, NH, C(O), C(O)O, C(O)NH, O(CO) and NHC(O);
- X1 is NH, O, or CH2;
- n1 is 0 or 1;
- X3 is absent or NRy;
- Rx and Ry are independently C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, or H, such as CH3 or H;
- L is O, S, S(O), S(O)2, NH, C(O), or CH2;
- Z1, Z2, and Z3 are independently selected from N and CH;
- R3 is selected from the group consisting of H, halo, C(O)NR2aR2b, C(O)OR2a, OR2a, NR2aR2b, OC(O)R2a, NR2aC(O)R2b, C1-4 alkyl optionally substituted with one or more halo, C2-4 alkenyl optionally substituted with one or more halo, and C2-4 alkynyl optionally substituted with one or more halo, wherein R2a and R2b are independently selected from the group consisting of H, C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl.
- In a further aspect, the present invention concerns a pharmaceutical composition comprising a compound according to the present invention and a pharmaceutically acceptable excipient or carrier.
- In another aspect, the present invention concerns the compound according to the present invention or the composition according to the present invention for use as a medicament.
- In still a further aspect, the present invention concerns the compound according to the present invention or the composition according to the present invention for use in the treatment of diseases responsive to inhibition of IL-1β, such as non-alcoholic steatoheptatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
-
FIG. 1 . Effect ofCompound 5 andCompound 7 on NAFLD activity score (NAS). -
FIG. 2 . Serum AST (U/L) levels after 28 days of treatment. -
FIG. 3 . Effect ofCompound -
FIG. 4 . Effect ofCompound 7 on lung hydroxyproline levels in the treatment of bleomycin-induced IPF. -
FIG. 5A . Total Cell Counts in BALF. -
FIG. 5B . Differential Leukocyte Counts in BALF. -
FIG. 6A . H&E Ashcroft Score. -
FIG. 6B . % Collagen Proportion Area (CPA). - In the present context, the term “C1-4 alkyl” is intended to mean a linear or branched hydrocarbon group having 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl.
- Similarly, the term “C2-4 alkenyl” is intended to cover linear or branched hydrocarbon groups having 2 to 4 carbon atoms and comprising a double bond. Examples of alkenyl groups are vinyl, allyl, and butenyl. Preferred examples of alkenyl are vinyl and allyl, especially allyl.
- In the present context the term “C2-4 alkynyl” is intended to mean a linear or branched hydrocarbon group having 2 to 4 carbon atoms and containing a triple bond. Illustrative examples of C2-4 alkynyl groups include acetylene, propynyl, butynyl, as well as branched forms of these. The position of unsaturation (the triple bond) may be at any position along the carbon chain. More than one bond may be unsaturated such that the “C2-4 alkynyl” is a di-yne as is known to the person skilled in the art.
- Herein, the term “halo” or “halogen” includes fluoro, chloro, bromo, and iodo, more particularly, fluoro, chloro and bromo.
- In the present context the term “aromatic ring or ring system” is intended to mean a fully or partially aromatic carbocyclic ring or ring system, such as phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracyl, phenanthracyl, pyrenyl, benzopyrenyl, fluorenyl and xanthenyl.
- The term “heteroaromatic ring or ring system” is intended to mean a fully or partially aromatic carbocyclic ring or ring system where one or more of the carbon atoms have been replaced with heteroatoms, e.g. nitrogen (═N- or —NH—), sulphur, and/or oxygen atoms. Examples of such heteroaromatic ring or ring system groups are oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, coumaryl, furyl, thienyl, quinolyl, benzothiazolyl, benzotriazolyl, benzodiazolyl, benzooxozolyl, phthalazinyl, phthalanyl, triazolyl, tetrazolyl, isoquinolyl, acridinyl, carbazolyl, dibenzazepinyl, indolyl, benzopyrazolyl, phenoxazonyl, benzofuranyl, dihydrobenzofuranyl and benzodioxolyl.
- In the present context, the term “heterocyclic ring or ring system” is intended to mean a non-aromatic carbocyclic ring or ring system where one or more of the carbon atoms have been replaced with heteroatoms, e.g. nitrogen (═N- or —NH—), sulphur, and/or oxygen atoms. Examples of such heterocyclic groups are imidazolidine, piperazine, hexahydropyridazine, hexahydropyrimidine, diazepane, diazocane, pyrrolidine, piperidine, azepane, azocane, aziridine, azirine, azetidine, pyroline, tropane, oxazinane (morpholine), azepine, dihydroazepine, tetrahydroazepine, hexahydroazepine, oxazolane, oxazepane, oxazocane, thiazolane, thiazinane, thiazepane, thiazocane, oxazetane, diazetane, thiazetane, tetrahydrofuran, tetrahydropyran, oxepane, tetrahydrothiophene, tetrahydrothiopyrane, thiepane, dithiane, dithiepane, dioxane, dioxepane, oxathiane and oxathiepane.
- In the present context, the term “optionally substituted” is intended to mean that the group in question may be substituted one or more times, preferably 1-2 times. Furthermore, the term “optionally substituted” may also mean that the group in question is unsubstituted.
- The compounds of the present invention can be in a free form or in the form of a pharmaceutically acceptable salt. In the context of the present invention, the term “pharmaceutically acceptable salt” is to be understood as a salt formed with either a base or an acid, wherein the resulting counter-ion does not significantly add to the toxicity of the compound of the present invention.
- Examples of pharmaceutically acceptable salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate or hydrobromide, etc., organic acid salts such as acetate, fumarate, oxalate, citrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate or maleate, etc. Also, when the compound has a substituent such as carboxyl group, there may be mentioned a salt with a base (for example, alkali metal salt such as sodium salt, potassium salt, etc. or alkaline earth metal salt such as calcium salt, etc.).
- Compounds
- The compounds of the invention are compounds of Formula I or pharmaceutically acceptable salts thereof:
- wherein
- R1 is an aromatic or heteroaromatic ring system optionally substituted with one or two substituents selected from the group consisting of C1-4 alkyl-Y1—, C2-4 alkenyl-Y1—, C2-4 alkynyl-Y1—, C1-4 alkyl-Y1— substituted with halo, such as fluoro, C2-4 alkenyl-Y1— substituted with halo, C2-4 alkynyl-Y1 substituted with halo, HO—C1-4 alkanediyl-Y1—, HO—C2-4 alkenediyl-Y1—, HO—C2-4 alkynediyl-Y1—, HO—C1-4 alkanediyl-, HO—C2-4 alkenediyl-, HO—C2-4 alkynediyl-, C1-4 alkyl- C2-4 alkenyl-, C2-4 alkynyl-, C1-4 alkyl substituted with halo, C2-4 alkenyl- substituted with halo, C2-4 alkynyl-substituted with halo, and halogen;
- Y1 is selected from the group consisting of O, S, NH, C(O), C(O)O, C(O)NH, O(CO) and NHC(O);
- X1 is NH, O, or CH2;
- n1 is 0 or 1;
- X3 is absent or NRy;
- Rx and Ry are independently C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, or H, such as CH3 or H;
- L is O, S, S(O), S(O)2, NH, C(O), or CH2;
- Z1, Z2, and Z3 are independently selected from N and CH;
- R3 is selected from the group consisting of H, halo, C(O)NR2aR2b, C(O)OR2a, OR2a, NR2aR2b, OC(O)R2a, NR2aC(O)R2b, C1-4 alkyl optionally substituted with one or more halo, C2-4 alkenyl optionally substituted with one or more halo, and C2-4 alkynyl optionally substituted with one or more halo, wherein R2a and R2b are independently selected from the group consisting of H, C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl.
- In one embodiment, the compound of formula I is a compound having the formula Ia:
- wherein
- R1 is selected from the group consisting of C1-4 alkyl-Y1—, C2-4 alkenyl-Y1—, C2-4 alkynyl-Y1—, C1-4 alkyl-Y1— substituted with halo, such as fluoro, C2-4 alkenyl-Y1-substituted with halo, C2-4 alkynyl-Y1 substituted with halo, HO—C1-4 alkanediyl-Y1—, HO—C2-4 alkenediyl-Y1—, HO—C2-4 alkynediyl-Y1—, HO—C1-4 alkanediyl-, HO—C2-4 alkenediyl-, HO—C2-4 alkynediyl-, C1-4 alkyl- C2-4 alkenyl-, C2-4 alkynyl-, C1-4 alkyl substituted with halo, C2-4 alkenyl- substituted with halo, C2-4 alkynyl- substituted with halo, and halogen;
- R2 is hydrogen; or
- R1 together with R2 forms an aromatic, heteroaromatic, cyclic or heterocyclic five- or six-membered ring optionally substituted with one or two substituents selected from the group consisting of C1-4 alkyl-Y1—, C2-4 alkenyl-Y1—, C2-4 alkynyl-Y1—, C1-4 alkyl-Y1— substituted with halo, such as fluoro, C2-4 alkenyl-Y1— substituted with halo, C2-4 alkynyl-Y1 substituted with halo, HO—C1-4 alkanediyl-, HO—C2-4 alkenediyl-, HO—C2-4 alkynediyl-, C1-4 alkyl- C2-4 alkenyl-, C2-4 alkynyl-, C1-4 alkyl substituted with halo, C2-4 alkenyl- substituted with halo, C2-4 alkynyl- substituted with halo, and halogen; and
- X1, n1, Y1, X3, Rx, Ry, L, Z1, Z2, Z3, R3 are as defined for the compound of formula I.
- In a further embodiment, in the compounds of formula I and formula Ia, X3 is NRy, giving rise to the compounds of formula II and Ha:
- X1, n1, Y1, Rx, Ry, L, Z1, Z2, Z3, R1, R2, R3 are as defined for the compounds of formula I and formula Ia.
- In still a further embodiment, in the compounds of formula II and formula IIa, R3 is in the para position, giving rise to the compounds of formula III and IIIa:
- X1, n1, Y1, Rx, Ry, L, Z1, Z2, Z3, R1, R2, R3 are as defined for the compounds of formula I and formula Ia.
- In yet a further embodiment, in the compounds of formula III and formula Ma, Z2 is CH, giving rise to the compounds of formula IV and IVa:
- X1, n1, Y1, Rx, Ry, L, Z1, Z3, R1, R2, R3 are as defined for the compounds of formula I and formula Ia.
- In one embodiment of the compounds according to the invention, Y1 is selected from the group consisting of O, S, NH, C(O), and C(O)NH. In a further embodiment, Y1 is selected from the group consisting of O, S, and NH. In yet a further embodiment, Y1 is O.
- In another embodiment of the compounds according to the invention, X1 is NH or O. In yet another embodiment, X1 is NH or O and n1 is 1.
- In a further embodiment of the compounds according to the invention, Rx and Ry are independently C1-4 alkyl. In yet a further embodiment, Rx and Ry are methyl.
- In one embodiment of the compounds according to the invention, L is selected from the group consisting of O, S, and CH2. In another embodiment, L is selected from the group consisting of O and CH2. In still another embodiment, L is O.
- In a further embodiment of the compounds according to the invention, Z1 is CH. In still a further embodiment, Z1 is CH and L is O. In yet a further embodiment, Z1 is CH, Z2 is CH, and L is O.
- In another embodiment of the compounds according to the invention, R3 is selected from the group consisting of H, halo, and C(O)NH2. In still another embodiment, R3 is selected from the group consisting of halo and C(O)NH2. In yet another embodiment, R3 is selected from the group consisting of Cl and C(O)NH2. In a further embodiment, R3 is Cl.
- In one embodiment of the compounds according to the invention having formula Ia, IIa, IIIa, or IVa, R2 is H.
- In another embodiment, the compounds of formula IVa have the following formula V:
- X1, Y1, Rx, Ry, R1, and R3 are as defined for the compounds of formula I and formula Ia. In a further embodiment of the compounds of formula V, X1 is O, R1 is C1-4 alkyl-O—, R3 is halo or C(O)NH2, and Rx and Ry are independently C1-4 alkyl.
- In a presently preferred embodiment, the compound according to the present invention is selected from the group consisting of:
- Pharmaceutical Formulation
- The compounds of the present invention are intended for use as a medicament. The compounds of the invention may in principle be applied on their own, but they are preferably formulated with a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier is an inert carrier suitable for each administration method, and can be formulated into conventional pharmaceutical preparation (tablets, granules, capsules, powder, solution, suspension, emulsion, injection, infusion, etc.). As such a carrier there may be mentioned, for example, a binder, an excipient, a lubricant, a disintegrant and the like, which are pharmaceutically acceptable. When they are used as an injection solution or an infusion solution, they can be formulated by using distilled water for injection, physiological saline, an aqueous glucose solution.
- The administration method of the compounds of the present invention is not particularly limited, and a usual oral or parenteral administration method (intravenous, intramuscular, subcutaneous, percutaneous, intranasal, transmucosal, enteral, etc.) can be applied.
- The dosage of the tetrahydroisoquinoline derivatives or a pharmaceutically acceptable salt thereof of the present invention may optionally be set in a range of an effective amount sufficient for showing a pharmacological effect, in accordance with the potency or characteristics of the compound to be used as an effective ingredient. The dosage may vary depending on administration method, age, body weight or conditions of a patient.
- Pharmaceutical Utility
- The compounds of the invention are intended for the treatment of diseases responsive to inhibition of IL-1β such as non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Hence, in one aspect, the invention concerns a compound or composition according to the invention for use as a medicament. In a further aspect, the invention concerns a compound or composition according to the invention for use in the treatment of diseases responsive to inhibition of IL-1β such as non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). In one embodiment, the disease responsive to inhibition of IL-1β is selected from the group consisting of non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), auto-inflammatory diseases, cardiovascular diseases, osteoarthritis, lung cancer and gout. In a further embodiment, the disease is NASH. In still a further embodiment, the disease is IPF.
- Preparation of Compounds—X1 as NRy
- The substituted pyridine-sulfonamides of formula II and IIa of the present invention are generally prepared via intermediate C, which is prepared as outlined in Scheme 1:
- In a
first step 5,6-dichloropyridin-3-sulfonamide A is alkylated to get intermediate compound B, which is then transformed in compound C through a Buchwald-type reaction with the corresponding bicyclic amine under microwave irradiation. - Depending on the identity of Rx, Ry, and R3, the preparation of intermediate C may require additional synthetic transformations, such as protection/de-protection reactions, from those described in Scheme 1.
- Depending on the presence and/or the identity of X1, the compounds according to the invention may be prepared according to Schemes 2b, 2c, or 2d.
- A Pd-catalyzed Suzuki-type reaction of intermediate compound C with the corresponding boronic acid at 150° C. under microwave irradiation leads to compounds of type IIb (such as compound 1; synthetic procedure as in Bioorg. Med. Chem. Lett. 2011, 21(10), 3152-3158).
- Pd-catalyzed Buchwald reaction of intermediate compound C with substituted anilines at 40° C. in the presence of a strong base yields compounds of type IIc (such as
compounds - Compounds of type IId (such as
compounds - Preparation of Compounds—X3 is Absent
- The substituted pyridine-sulfonamides of formula I and Ia of the present invention, wherein X3 is absent, are generally prepared via intermediate E, which is prepared as outlined in Scheme 3:
- Analogous procedure to the preparation of intermediate compound C but using D-type compound as the starting material, for example 2,3-dichloro-5-(methylsulfonyl)pyridine in the case of the synthesis of final compound 11.
- To a suspension of commercially available 5,6-dichloropyridin-3-sulfonamide A (1 eq) and K2CO3 (2 eq) in anhydrous DMF (1 ml/eq) iodomethane (2 eq) in DMF (5 ml/mmol) was added and the resulting mixture was stirred at room temperature until reaction was completed (overnight, TLC control). Then the solvent was evaporated and ethyl acetate was added. The organic mixture was washed twice with water and the organic layer was dried with magnesium sulphate. After evaporation of the solvent the resulting crude product was pure enough to be used in Example 2 without purification (yellow solid, 95% yield)
- A mixture of the compound obtained in Example 1 (1 eq), commercially available 4-(4-chlorophenoxy)piperidine hydrochloride (1.2 eq) and TEA (2.2 eq) in EtOH (4.8 ml/mmol) was heated first at 80° C. for 5 min and then at 120° C. for 30 min under microwave irradiation (200 W) (HPLC control). Then the solvent was evaporated and ethyl acetate was added; the organic mixture was washed twice with water and the combined organic layers were dried with magnesium sulphate. After that solvent was evaporated and the resulting crude product was pure enough to be used in subsequent Examples without purification (clear brown solid, 91% yield).
- A mixture of the compound obtained in Example 1 (1 eq), commercially available 4-(piperidin-4-yloxy)pyridine-2-carboxamide (1.2 eq) and TEA (2.2 eq) in EtOH (4.8 ml/mmol) was heated first at 80° C. for 5 min and then at 120° C. for 30 min under microwave irradiation (200 W) (HPLC control). Then the solvent was evaporated and ethyl acetate was added; the organic mixture was washed twice with water and the combined organic layers were dried with magnesium sulphate. After that solvent was evaporated and the resulting crude product was enough pure to be used in the next step without purification (clear white solid, 93% yield).
- A solution of the intermediate obtained in Example 2 (1 eq.), benzo[b]furan-5-boronic acid (1.1 eq), potassium carbonate (1.4 eq) and Pd(PhPh3)4 (0.1 eq) in DME (5 ml/mmol) was heated at 150° C. under microwave irradiation (200 W) for 1 h (or overnight at 150° C.). Then the crude mixture was diluted with EtOAc, filtered through a Celite plug, washed with EtOAc and MeOH, and the solvent was evaporated. The resulting crude product was purified by Isolera Biotage system (C18, acetonitrile/water) to yield pure product. White foam, 45% total yield, 98% HPLC purity.
- 1HNMR (CDCl3, 400 MHz): δ (ppm)=8.51 (d, 1H), 7.68 (d, 1H), 7.33 (s, 1H), 7.27 (s, 1H), 7.22 (d, 2H), 6.86-6.81 (m, 3H), 4.64 (t, 2H), 4.42-4.38 (m, 2H), 3.61-3.55 (m, 2H), 3.27 (t, 2H), 3.19-3.18 (m, 2H), 2.76 (s, 6H), 1.94-1.89 (m, 2H), 1.76-1.70 (m, 2H). C26H29ClN3O4S
- MS (electrospray): m/z=514.1583 (M+1).
- A screw-cap test-tube, equipped with a magnetic stir bar, was charged with BrettPhos-precatalyst (4 mol %), 2,3-dihydrobenzo[b]furan-5-amine (1 eq.) and the intermediate compound obtained in Example 2 (1 eq.). The vial was sealed with a teflon screw-cap, evacuated and backfilled with nitrogen; this procedure was repeated two additional times. Then, LiHMDS (1M in THF, 2.5 eq.) was added. The reaction mixture was stirred at 40° C. until reaction was completed (2.5 h). The solution was allowed to cool to room temperature, quenched by the addition of aqueous, saturated NH4Cl solution (5 mL) and then diluted with EtOAc. The organic phase was separated and the aqueous phase was extracted one more time with EtOAc. The combined organic phases were washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and the crude was purified by Isolera Biotage System (C18, acetonitrile/water) yielding impure product (115.7 mg), which was purified again by the same system. Brown solid, 6% total yield, 96% HPLC purity (254 nm). 1HNMR (CDCl3, 400 MHz): δ (ppm)=8.34 (s, 1H), 7.96 (bs, 1H), 7.24 (dd, 2H), 7.03 (s, 1H), 6.96 (dd, 1H), 6.85-6.79 (m, 3H), 5.88 (s, 1H), 4.63 (t, 2H), 4.48 (m, 1H), 3.76-3.73 (m, 2H), 3.45 (m, 2H), 3.23 (t, 2H), 2.80 (s, 6H), 1.99-1.94 (m, 2H), 1.82 (m, 2H). C26H30ClN4O4S,
- MS (electrospray): m/z=529.1677 (M+1).
- 2,3-dihydro-5-hydroxybenzo[b]furan (1.1 eq) and cesium carbonate (1.2 eq) were taken in anhydrous DMF (1.2 ml/mmol) and treated with neat sodium hydride (1.1 eq). After hydrogen evolution ceased, the intermediate compound obtained in Example 2 (1 eq) was added and the reaction was stirred at 150° C. until no further evolution of reaction in a sealed pressure tube (overnight) or under microwave irradiation (200 W) (2 h). Then solvent was removed under vacuum and the crude product was diluted with ethyl acetate (6 ml/mmol) and water (6 ml/mmol). The aqueous layer was extracted with ethyl acetate three times. The organic layer was washed with 2N NaOH, dried and concentrated under vacuum. Crude product was purified by Isolera Biotage system (C18, acetonitrile-water gradient) to yield impure product, which was purified by preparative chromatography (silica, hexane/ethyl acetate 4:1). Clear oil, 12% total yield, 100% HPLC purity (254 nm).
- 1HNMR (CDCl3, 400 MHz): δ (ppm)=8.30 (dd, 1H), 7.247-7.22 (m, 3H), 6.86-6.81 (m, 3H), 6.75-6.70 (m, 2H), 4.61 (t, 2H), 4.50-4.47 (m, 1H), 4.00-3.97 (m, 2H), 3.66-3.63 (m, 2H), 3.21 (t, 2H), 2.67 (s, 6H), 2-06-1.99 (m, 2H), 1.90-1.84 (m, 2H). C26H28ClN3O5S
- MS (electrospray): m/z=530.1550 (M+1).
- 4-ethoxyphenol (1.1 eq) and cesium carbonate (1.2 eq) were taken in anhydrous DMF (1.2 ml/mmol) and treated with neat sodium hydride (1.1 eq). After hydrogen evolution ceased, the intermediate obtained in Example 2 (1 eq) was added and the reaction was stirred at 150° C. until no further evolution of reaction in a sealed pressure tube (overnight) or under microwave irradiation (200 W) (2 h). Then solvent was removed under vacuum and the crude product was diluted with ethyl acetate (6 ml/mmol) and water (6 ml/mmol). The aqueous layer was extracted with ethyl acetate three times. The organic layer was washed with 2N NaOH, dried and concentrated under vacuum. Crude product was purified by Isolera Biotage system (C18, acetonitrile-water gradient), recovering unreacted starting material and pure product. Clear brown solid, 41% yield, 100% HPLC purity (254 nm).
- 1HNMR (CDCl3, 400 MHz): δ (ppm)=8.31 (d, 1H), 7.26-7.23 (m, 4H), 6.88-6.84 (m, 5H), 4.51-4.46 (1H, m), 4.05-4.00 (m, 4H), 3.66-3.59 (m, 2H), 2.67 (s, 6H), 2.00-1.86 (m, 2H), 1.86-1.83 (m, 2H), 0.43 (t, 3H). C26H30ClO5S
- MS (electrospray): m/z=532.1680 (M+1).
- 4-ethoxyphenol (1.1 eq) and cesium carbonate (1.2 eq) were taken in anhydrous DMF (1.2 ml/mmol) and treated with neat sodium hydride (1.1 eq). After hydrogen evolution ceased, the intermediate obtained in Example 3 (1 eq.) was added and the reaction was stirred at 150° C. until no further evolution of reaction in a sealed pressure tube (overnight) or under microwave irradiation (200 W) (3 h). Then solvent was removed under vacuum and the crude product was diluted with ethyl acetate (6 ml/mmol) and water (6 ml/mmol). The aqueous layer was extracted with ethyl acetate three times. The organic layer was washed with 2N NaOH, dried and concentrated under vacuum. Crude product was purified by Isolera Biotage system (C18, acetonitrile-water gradient), recovering unreacted starting material and pure product. Clear brown solid, 16% yield, 100% HPLC purity (254 nm).
- 1HNMR (CDCl3, 400 MHz): δ (ppm)=8.38 (d, 1H), 8.34 (s, 1H), 6.98-6.97 (m, 1H), 6.89 (s, 1H), 5.59 (bs, 1H), 4.79-4.75 (m, 1H), 4.06-3.63 (m, 4H), 3.69-3.63 (m, 2H), 2.68 (s, 6H), 2-10-2.06 (m, 2H), 1.92-1.88 (m, 2H), 1.44 (t, 3H). C26H31N5O6S
- MS (electrospray): m/z=542.2084 (M+1).
- 2,3-dihydro-5-hydroxybenzo[b]furan (1.1 eq) and cesium carbonate (1.2 eq) were taken in anhydrous DMF (1.2 ml/mmol) and treated with neat sodium hydride (1.1 eq). After hydrogen evolution ceased, the intermediate obtained in Example 3 (1 eq) was added and the reaction was stirred at 150° C. until no further evolution of reaction in a sealed pressure tube (overnight) or under microwave irradiation (200 W) (2.5 h). Then solvent was removed under vacuum and the crude product was diluted with ethyl acetate (6 ml/mmol) and water (6 ml/mmol). The aqueous layer was extracted with ethyl acetate three times. The organic layer was washed with 2N NaOH, dried and concentrated under vacuum. Crude product was purified by IsoleraBiotage system (C18, acetonitrile-water gradient), recovering unreacted starting material and pure product. White foam, 13% yield, 98% HPLC purity (254 nm).
- 1HNMR (CDCl3, 400 MHz): δ (ppm)=8.38 (d, 1H), 8.31 (d, 1H), 7.24 (d, 1H), 6.97-6.96 (m, 1H), 6.82 (d, 1H), 6.76-6.69 (m, 2H), 5.63 (bs, 1H), 4.79-4.76 (m, 2H), 4.62 (t, 2H), 4.02-4.00 (m, 2H), 3.68-3.63 (m, 2H), 3.22 (t, 2H), 2.68 (s, 6H), 2.12-2.08 (m, 2H), 1.93-1.89 (m, 2H). C26H29N5O6S
- MS (electrospray): m/z=540.1944 (M+1).
- Analogous procedure to the synthesis of the intermediate compound according to Example 2, but using commercially available 2,3-dichloro-5-(methylsulfonyl)pyridine as starting material. White solid, 96% total yield.
- Analogous procedure to the synthesis of
compounds - 1HNMR (CDCl3, 400 MHz): δ (ppm)=8.45 (s, 1H), 7.35 (d, 1H), 7.26 (dd, 2H), 6.85 (d, 2H), 4.52-4.48 (m, 1H), 4.04-4.00 (m, 4H), 3.72-3.66 (m, 2H), 3.01 (s, 3H), 2.05-1.99 (m, 2H), 1.90-1.84 (m, 2H), 1.43 (t, 3H). C25H28ClN2O5S
- MS (electrospray): m/z=503.1398 (M+1).
- Materials
-
Catalog S.No Materials Number Supplier 1 LEGEND MAX human IL-1β 437008 Biolegend ELISA kit 2 RPMI 1640 cell culture R6504 Sigma- Aldrich medium 3 Phosphate buffered saline P3813 Sigma-Aldrich 4 Dimethyl Sulfoxide D2650 Sigma- Aldrich 5 Foetal Bovine Serum 10270-106 Gibco 6 Penicillin-Streptomycin 15140-122 Gibco 7 Histopaque-1077 10771 Sigma-Aldrich 8 Sodium Citrate Tribasic 91150 Sigma-Aldrich Solution 9 ‘V’ bottom polypropylene 15160 Griener 96 well Micro Plate 10 Recombinant human GM- 572902 Biolegend CSF 11 LipoPolySaccharide (LPS) L6529 Sigma- Aldrich 12 CellTiter-Glo ® luminescent G7570 Promega assay kit - Preparation of RPMI 1640 Growth Medium
- RPMI 1640 basal medium was prepared according to the manufacturer's instructions on the data sheet. A sterility check was carried out using 5 mL of medium for 48 hours at 37° C. incubator with constant supply of 5% CO2. Following the sterility check, the basal medium was made complete by addition of FBS and Pen/Strep antibiotic. The medium was stored at 4° C. until further use.
- Preparation of Phosphate-Buffered Saline (PBS)
- A single sachet of PBS was dissolved in a litre of Milli-Q water. PBS was filtered through a 0.22 μm filter membrane and stored at 4° C. until further use.
- Preparation of Peripheral Blood Mononuclear Cells (PBMC)
- 5 mL of RPMI media without serum (1:1) was added to a sample of 5 mL of human whole blood in EDTA or sodium citrate and mixed well by inversion. 3 mL of Histopaque-1077 was added to a 15 mL conical centrifuge tube and brought to room temperature. Using a transfer pipette, 10 mL of the blood-RPMI mixture was carefully layered onto the Histopaque-1077 and was centrifuged at 400×g for exactly 30 minutes at room temperature.
- After centrifugation, a pasteur pipette was used to aspirate the upper layer to within 0.5 cm of the opaque interface containing the mononuclear cells. The upper layer was discarded. With a Pasteur pipette, the opaque interface was carefully transferred to a clean conical centrifuge tube. 5 mL RPMI was added to the tube and mixed by inversion, followed by centrifugation at 250×g for exactly 10 minutes. The supernatant was aspirated and discarded.
- The leukocyte pellet was re-suspended with 5 mL RPMI and mixed gently with a Pasteur pipette, followed by centrifugation at 250×g for exactly 10 minutes. The pellet was washed 3X with PBS and re-suspended in RPMI medium.
- The number of viable PBMCs/mL was counted.
- Counting PBMCs
- 10 μL of PBMC suspension was diluted with 90 μL of PBS medium (1:10 dilution). 20 μL of cell suspension was added to 20 μL of trypan blue solution (1:1 ratio) and was mixed carefully to avoid aerosol formation. A haemocytometer was loaded with cell culture mixture until the area under the coverslip was sufficiently filled. The suspension was allowed to settle in the haemocytometer for at least 10 seconds before counting.
- The viable cells were counted in four corner 1 mm squares of one chamber, as well as the number of dead cells. Viable PBMCs are clear; non-viable PBMCs are blue. Cells that touched either the top line or vertical perimeter line of any corner square were included. Cells that touched either the bottom line or right vertical perimeter line of any corner square were not counted.
- Calculation of Cell Count
- Calculation of the number of viable PBMCs/mL:
-
PBMC/mL=PBMC in all four squares×10×2×104/4 - 104=Volume conversion factor to 1 mL;
- 10=dilution factor of cell suspension;
- 2=Dilution factor with trypan blue
-
Total cell count=PBMC/mL×Total volume (mL) of PBMC suspension -
% Cell viability=(Number of viable cells counted/total number of cells counted (viable+dead))×100 - Cell Seeding, Differentiation and Treatment
- 2×105 PBMCs at a total volume of 200 μL/well were plated into a 96-well plate and incubated for 4 hrs at 37° C. in a CO2 incubator to allow the monocytes to settle, leaving the lymphocytes in suspension. Following incubation, 100 μL were aspirated out of each well to ensure removal of the lymphocyte population.
- The monocytes were differentiated to macrophages by addition of 200 ng/mL of recombinant human GM-CSF (4 mg/mL stock) and incubated at 37° C./5% CO2 for 6 days. The medium was changed every two days by removing half the volume of medium in the well and re-supplementing with fresh RPMI complete medium and recombinant human GM-CSF.
- Following differentiation, the cells were treated in duplicates with a compound according to the invention in a total volume of 50 μL, maintaining a final DMSO percentile of 0.5%. The plate was transferred to an incubator maintained at 37° C./5% CO2 for 2 hours. The cells were stimulated with 100 ng/mL of LPS (4×) (1 mg/mL stock) in a total volume of 50 μL.
- The plate was transferred to an incubator maintained at 37° C./5% CO2 for 16 hours.
- Cytokine Estimation by ELISA
-
- 1. Each well from a pre-coated ELISA plate was aspirated and washed with wash buffer (0.05
% Tween 20 in PBS; pH 7.2-7.4) by filling each well with wash buffer (300 μL). The process was repeated two times for a total of three washes. The liquid was removed completely at each step. After the last wash, any remaining wash buffer was removed. - 2. Plates were blocked by adding 300 μL of block buffer (1% BSA in PBS) to each well and incubated at room temperature for 1 hour.
- 3. The aspiration/wash as in step 1 was repeated.
- 4. 100 μL of sample or standard prepared in reagent diluent (0.1% BSA, 0.05
% Tween 20 in PBS pH7.2-7.4) was added. The wells were covered with an adhesive strip and incubated for 2 hours at room temperature. - 5. The aspiration/wash as in step 1 was repeated.
- 6. 100 μL of detection antibody, diluted in reagent diluent, was added to each well. The wells were covered with a new adhesive strip and incubated for 2 hours at room temperature.
- 7. The aspiration/wash as in step 1 was repeated.
- 8. 100 μL of the working dilution (1:200 from the stock) and streptavidin-HRP was added to each well. The plate was covered and incubated for 20 minutes at room temperature.
- 9. 100 μL of substrate solution (1:1 mixture of H2O2 and tetramethylbenzidine) was added to each well and incubated for 20 minutes at room temperature.
- 10.50 μL of stop solution (2N H2SO4) was added to each well. The plate was tapped gently to ensure thorough mixing.
- 11. The optical density of each well was determined immediately using a microplate reader (Spectramax Plus) set to 450 nm.
- 1. Each well from a pre-coated ELISA plate was aspirated and washed with wash buffer (0.05
- Cytokine Viability Assessment
- 100 μl/well volume of CellTiter-Glo® luminescent reagent was added to the assay plates and incubated at room temperature for 30 mins on a plate shaker. Following incubation, the luminescent signal of each well was determined using a microplate reader (Perkin Elmer ENVISION 2104).
- Data Analysis
- % Inhibition of the test compounds was determined utilizing the following formula:
-
% Inhibition=100−(100*(Average Test Compound Counts−Average Negative Control Counts)/(Average Positive Control Counts−Average Negative Control Counts)) - All of the “Counts” stated in this formula are derived from “Optical Density values” determined as described above using the microplate reader (step 11).
- Cytotoxicity of the test compounds was determined utilizing the following formula:
-
% Cytotoxicity=100−(100*(Average Test Compound Counts−Average Negative Control Counts)/(Average Positive Control Counts−Average Negative Control Counts)) - All of the “Counts” stated in this formula are derived from “luminescent signal” determined as described for the cytokine viability assessment.
- Results
-
IC50 (IL-Iβ inhibition) Cell viability Compound 1 115 nM 100 % Compound 2 29 nM 100 % Compound 3 121 nM 100% Compound 4 300 nM 100 % Compound 5 28 nM 100% Compound 6 13 nM 100 % Compound 7 27 nM 100% Compound 8 337 nM 100% Compound 9 531 nM 100 % Compound 10 410 nM 100% Compound 11 753 nM 100 % Compound 12 2.3 μM 100% - Various concentrations of Recombinant Human MAPK8 dissolved in water were manually printed onto a bare gold-coated (thickness 47 nm) PlexArray Nanocapture Sensor Chip (Plexera Bioscience, Seattle, Wash., US) at 40% humidity. Each concentration was printed in replicate, and each spot contained 0.2 μL of the protein solution. The chip was incubated in 80% humidity at 4° C. overnight, and rinsed with 10×PBST for 10 min, lx PBST for 10 min, and deionized water twice for 10 min. The chip was then blocked with 5% (w/v) non-fat milk in water overnight, and washed with 10×PBST for 10 min, lx PBST for 10 min, and deionized water twice for 10 min before being dried under a stream of nitrogen prior to use.
- Surface Plasmon Resonance Imaging (SPRi) measurements were performed with PlexAray HT (Plexera Bioscience, Seattle, Wash., US). Collimated light (660 nm) passes through the coupling prism, reflects off the SPR-active gold surface, and is received by the CCD camera. Buffers and samples were injected by a non-pulsatile piston pump into the 30 μL flowcell that was mounted on the coupling prism. Each measurement cycle contained four steps: washing with PBST running buffer at a constant rate of 2 μL/s to obtain a stable baseline, sample injection at 5 μL/s for binding, surface washing with PBST at 2 μL/s for 300 s, and regeneration with 0.5% (v/v) H3PO4 at 2 μL/s for 300 s. All the measurements were performed at 4° C.
- The signal changes after binding and washing were recorded in AU as the assay value. Selected protein-grafted regions in the SPR images were analyzed, and the average reflectivity variations of the chosen areas were plotted as a function of time. Real-time binding signals were recorded and analyzed by Data Analysis Module (DAM, Plexera Bioscience, Seattle, Wash., US). Kinetic analysis was performed using BIAevaluation 4.1 software (Biacore, Inc.).
- The equilibrium dissociation constant (KD Value) determined for
Compound 7 was 3.41×10−8 M. (Ka=2.29×104 M−1·s−1, Kd=7.82×10−4s−1) - Various concentrations of p38 MAPK dissolved in water were manually printed onto a bare gold-coated (thickness 47 nm) PlexArray Nanocapture Sensor Chip (Plexera Bioscience, Seattle, Wash., US) at 40% humidity. Each concentration was printed in replicate, and each spot contained 0.2 μL of protein solution. The chip was incubated in 80% humidity at 4° C. for overnight, and rinsed with 10×PBST for 10 min, lx PBST for 10 min, and deionized water twice for 10 min. The chip was then blocked with 5% (w/v) non-fat milk in water overnight, and washed with 10×PBST for 10 min, lx PBST for 10 min, and deionized water twice for 10 min before being dried under a stream of nitrogen prior to use.
- Surface Plasmon Resonance Imaging (SPRi) measurements were performed with PlexAray HT (Plexera Bioscience, Seattle, Wash., US). Collimated light (660 nm) passes through the coupling prism, reflects off the SPR-active gold surface, and is received by the CCD camera. Buffers and samples were injected by a non-pulsatile piston pump into the 30 μL flowcell that was mounted on the coupling prism. Each measurement cycle contained four steps: washing with PBST running buffer at a constant rate of 2 μL/s to obtain a stable baseline, sample injection at 5 μL/s for binding, surface washing with PBST at 2 μL/s for 300 s, and regeneration with 0.5% (v/v) H3PO4 at 2 μL/s for 300 s. All the measurements were performed at 4° C.
- The signal changes after binding and washing (in AU) are recorded as the assay value. Selected protein-grafted regions in the SPR images were analyzed, and the average reflectivity variations of the chosen areas were plotted as a function of time. Real-time binding signals were recorded and analyzed by Data Analysis Module (DAM, Plexera Bioscience, Seattle, Wash., US). Kinetic analysis was performed using BIAevaluation 4.1 software (Biacore, Inc.).
- The equilibrium dissociation constant (KD Value) determined for
Compound 7 was 1.19×10−8 M. (Ka=2.08×104 M−1·s−1, Kd=2.48×10−4s−1) - NASH Induction
- Timed pregnant mice (n=30) were selected for the study. The delivered pups were subcutaneously injected on the post-natal day 2 (PND-2) with 200 μg of Streptozotocin and were allowed to remain with the mother until they reached the weanling age. After weanling, the male pups were selected and fed with 60% kcal fat diet (Research Diet-D12492) for the next 2 weeks. All the animals were observed twice daily for clinical signs.
- Study Procedure
- Mice were dosed with vehicle, test compounds and reference compound (elafibranor) twice daily morning (9.00 AM) and evening before the start of dark cycle (6:00 PM) from
day 0 to 28. - Animal body weight measurements were made daily for the complete duration of the experiment.
- Animals were dosed for 28 days (from week 6 to 10) with the test and reference compounds.
- Blood glucose was estimated before the treatment start and on the termination day 28. Serum ALT and AST levels were measured from the plasma before the treatment start and on day 28.
- Histopathology analysis including H&E staining, Masson's trichrome staining and Oil-Red-O (ORO) staining was performed for the liver tissues.
- Sample Analysis
- NAFLD (Non Alcoholic Fatty Liver Disease) Scoring: H&E Staining
- All the H&E stained tissue sections were examined by light microscopy. As per the below grading system (Kleiner et al., 2005) in 200× objective lens, NAFLD scoring was done for steatosis, lobular inflammation and hepatic ballooning.
- Collagen Proportion Area (% CPA) Measurement: Masson's Trichrome Staining
- All the Masson's trichrome stained tissue sections were examined by light microscopy in 100× objective lens. Randomly selected five fields (approx 684.85 μm×917.11 m per field) from each liver were subjected to collagen proportion area measurement by using Image Pro Premier 9.1 software. The percentage of collagen proportion area was calculated by dividing collagen tissue area by total tissue area.
- Percent Stained Area Measurement: Oil Red O staining
- All the Oil-Red-O stained tissue sections were examined by light microscopy in 100× objective lens. Randomly selected five fields (approximately 688.33 μm×922.45 μm per field) from each liver were subjected to measure stained area by using Image Pro Premier 9.1 software. The percentage of stained area was calculated by dividing lipid stained tissue area by total tissue area.
- The effect of
Compound 5 andCompound 7 on NAFLD activity score (NAS) is shown inFIG. 1 . - The study clearly demonstrated that
Compound 7 at the 3 mg/kg dose significantly reduced steatosis and lobular inflammation in the liver and showed better NAS score than Elafibranor. -
Compound 5 at the 3 mg/kg dose significantly reduced lobular inflammation and showed a trend towards decreased steatosis and hepatic ballooning resulting in significant reduced NAS score than disease controls. -
Compounds FIG. 2 - Unlike the reference compound (Elafibranor), both test compounds (
Compounds 5 and 7) did not show any hepatomegaly and increase in liver to body weight ratio as shown inFIG. 3 - In conclusion, the tested compounds lead to significant improvement in liver chemistry and histological activity of NASH. The therapeutic profile of
Compounds - IPF Induction
- Timed pregnant mice (n=30) were selected for the study. The delivered pups were subcutaneously injected on the post-natal day 2 (PND-2) with 1.5 U/kg of Bleomycin (intra-tracheal) and were allowed to remain with the mother until they reached the weanling age. After weanling, the male pups were selected and fed with 60% kcal fat diet (Research Diet-D12492) for the next week. All the animals were observed twice daily for clinical signs.
- Study Procedure
- Mice were orally dosed with vehicle, test compounds and reference compound (Pirfenidone) twice daily morning (9.00 AM) and evening before the start of dark cycle (6:00 PM) from
day 0 to 14. - Animal body weight measurements were made daily for the complete duration of the experiment.
- Animals were dosed for 14 days with the test and reference compounds.
- Lung hydroxyproline level was estimated before the treatment start and on the
termination day 14. Total cell count and differential leukocyte count in BALF were measured before the treatment start and on day 28. - Histopathology analysis in the form of H&E Ashcroft score was performed for the lung tissues.
- Sample Analysis
- IPF Scoring: H&E Staining
- All the H&E stained tissue sections were examined by light microscopy. As per the below grading system (Kleiner et al., 2005) in 200× objective lens, IPF scoring was carried out.
- Collagen Proportion Area (% CPA) Measurement: Masson's Trichrome Staining
- All the Masson's trichrome stained tissue sections were examined by light microscopy in 100× objective lens. Randomly selected five fields (approx 684.85 μm×917.11m per field) from each lung were subjected to collagen proportion area measurement by using Image Pro Premier 9.1 software. The percentage of collagen proportion area was calculated by dividing collagen tissue area by total tissue area.
- The effect of
Compound 7 on lung hydroxyproline levels is shown inFIG. 4 . - Lung hydroxyproline levels were significantly increased in Bleomycin control in comparison to Naïve control. The study clearly demonstrated that
Compound 7 at the 15 mg/kg dose significantly reduced lung hydroxyproline levels and that the reduction was higher than for 100 mg/kg Pirfenidone. - In BALF, total and Differential leukocyte (macrophage and lymphocyte) counts were significantly increased in Bleomycin control group. BALF macrophage counts were reduced with Compound 7 (p>0.05) and Pirfenidone (p<0.05) treatment as compared with Bleomycin control as shown in
FIGS. 5A and 5B . - Fibrosis score and % CPA were significantly increased in Bleomycin control lungs in comparison to Naïve control. Compound 7 (p<0.05) and Pirfenidone (p<0.05) treated lung samples exhibited a significant reduction in both fibrosis score and % CPA in comparison with Bleomycin control as shown in
FIGS. 6A and 6B . The data is in line with hydroxyproline results. - In conclusion, the tested compound leads to significant improvement in lung chemistry and histological activity of IPF. The therapeutic profile of
Compound 7 suggests that it has a potential for the treatment of human IPF. All treated animals presented body weight gain compared to Bleomycin control and had no clinical signs of toxicity or side effects.
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18380017 | 2018-11-14 | ||
EP18380017 | 2018-11-14 | ||
PCT/EP2019/081410 WO2020099603A1 (en) | 2018-11-14 | 2019-11-14 | Pyridin-sulfonamide compounds for the treatment of conditions related to interleukin 1 beta |
Publications (2)
Publication Number | Publication Date |
---|---|
US20220002276A1 true US20220002276A1 (en) | 2022-01-06 |
US12071431B2 US12071431B2 (en) | 2024-08-27 |
Family
ID=64959178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/293,877 Active 2041-08-17 US12071431B2 (en) | 2018-11-14 | 2019-11-14 | Pyridin-sulfonamide compounds for the treatment of conditions related to interleukin 1 beta |
Country Status (10)
Country | Link |
---|---|
US (1) | US12071431B2 (en) |
EP (1) | EP3880668B1 (en) |
JP (1) | JP7395198B2 (en) |
KR (1) | KR20210093293A (en) |
CN (1) | CN113316571A (en) |
AU (1) | AU2019379789B2 (en) |
CA (1) | CA3119399A1 (en) |
ES (1) | ES2970881T3 (en) |
MX (1) | MX2021005688A (en) |
WO (1) | WO2020099603A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466012B2 (en) | 2018-01-10 | 2022-10-11 | Allinky Biopharma | Tetrahydroisoquinoline compounds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018183145A1 (en) * | 2017-03-26 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1651606B1 (en) * | 2003-07-30 | 2012-10-24 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
US20090247499A1 (en) | 2006-08-21 | 2009-10-01 | Fletcher Joan M | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
US20080176861A1 (en) * | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
PL2364975T3 (en) * | 2008-10-27 | 2013-12-31 | Mitsubishi Tanabe Pharma Corp | Novel amide derivative and use thereof as medicine |
JP2011246461A (en) * | 2010-04-27 | 2011-12-08 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition containing new amide derivative |
DK2565182T3 (en) * | 2010-04-27 | 2017-12-04 | Mitsubishi Tanabe Pharma Corp | New amide derivative and its use as a drug |
JP5800786B2 (en) * | 2011-10-26 | 2015-10-28 | 田辺三菱製薬株式会社 | Pharmaceutical composition containing a novel amide derivative as an active ingredient |
KR20180041662A (en) * | 2015-07-09 | 2018-04-24 | 미쓰비시 타나베 파마 코퍼레이션 | New imide derivatives and uses thereof as medicines |
JP6856555B2 (en) * | 2017-01-06 | 2021-04-07 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
US11466012B2 (en) | 2018-01-10 | 2022-10-11 | Allinky Biopharma | Tetrahydroisoquinoline compounds |
-
2019
- 2019-11-14 CN CN201980089099.8A patent/CN113316571A/en active Pending
- 2019-11-14 US US17/293,877 patent/US12071431B2/en active Active
- 2019-11-14 EP EP19805623.6A patent/EP3880668B1/en active Active
- 2019-11-14 MX MX2021005688A patent/MX2021005688A/en unknown
- 2019-11-14 KR KR1020217018060A patent/KR20210093293A/en unknown
- 2019-11-14 WO PCT/EP2019/081410 patent/WO2020099603A1/en unknown
- 2019-11-14 AU AU2019379789A patent/AU2019379789B2/en active Active
- 2019-11-14 ES ES19805623T patent/ES2970881T3/en active Active
- 2019-11-14 JP JP2021525717A patent/JP7395198B2/en active Active
- 2019-11-14 CA CA3119399A patent/CA3119399A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018183145A1 (en) * | 2017-03-26 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466012B2 (en) | 2018-01-10 | 2022-10-11 | Allinky Biopharma | Tetrahydroisoquinoline compounds |
Also Published As
Publication number | Publication date |
---|---|
KR20210093293A (en) | 2021-07-27 |
CA3119399A1 (en) | 2020-05-22 |
JP7395198B2 (en) | 2023-12-11 |
EP3880668C0 (en) | 2023-12-20 |
WO2020099603A1 (en) | 2020-05-22 |
AU2019379789A1 (en) | 2021-05-27 |
ES2970881T3 (en) | 2024-05-31 |
EP3880668A1 (en) | 2021-09-22 |
JP2022507244A (en) | 2022-01-18 |
CN113316571A (en) | 2021-08-27 |
MX2021005688A (en) | 2021-07-07 |
AU2019379789B2 (en) | 2024-03-28 |
US12071431B2 (en) | 2024-08-27 |
EP3880668B1 (en) | 2023-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3464266B1 (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
JP2020536110A (en) | Chemical compounds | |
JP2021523919A (en) | 1,3-thiazole-2-yl-substituted benzamide for treating diseases associated with nerve fiber sensitization | |
US20090233906A1 (en) | Imidazoazepinone compounds | |
TW202216694A (en) | Methods of treating cancer using heteroaryl-biphenyl amide derivatives | |
US20210332057A1 (en) | Aminonorbornane derivative and manufacture method therefor and use thereof | |
CN101801386A (en) | Anti-angiogenic agents and methods of use | |
JP2021502987A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
KR20130031229A (en) | Composition for preventing and treating autoimmune diseases comprising metformin | |
US12071431B2 (en) | Pyridin-sulfonamide compounds for the treatment of conditions related to interleukin 1 beta | |
US7985746B2 (en) | Imidazoazepinone compounds | |
US20240050395A1 (en) | Deuterated oxophenylarsine compound and use thereof | |
WO2009064431A1 (en) | Methods of use | |
RU2803242C2 (en) | Pyridine sulfonamide compounds for the treatment of conditions associated with interleukin 1 beta | |
WO2023284869A1 (en) | Sulfur/phosphorus-containing aryl compound and application thereof | |
US20230100235A1 (en) | Anticancer agent composition | |
TWI769470B (en) | Combination of a FAK inhibitor and a BTK inhibitor for the treatment of disease | |
KR20100088695A (en) | Enantiomerically enriched imidazoazepinone compounds | |
WO2014191822A1 (en) | BENZOIC ACID DERIVATIVES AS IL-15Rα RECEPTOR INHIBITORS | |
CN101137379B (en) | Cxcr4 antagonists for the treatment of HIV infection | |
US20230190763A1 (en) | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | |
JP2020075893A (en) | AGENTS FOR TREATING AND PREVENTING IgG4-ASSOCIATED DISEASES | |
JP2022102931A (en) | Anti-inflammatory agent | |
WO2014191823A1 (en) | Amine derivatives as il-15 activity inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: ALLINKY BIOPHARMA, SPAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VEGA, MIGUEL;CARRASCO, ESTHER;GOMEZ, PATRICIA;AND OTHERS;SIGNING DATES FROM 20210703 TO 20210707;REEL/FRAME:057201/0434 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |